Quarterly report pursuant to Section 13 or 15(d)

Notes Payable

v3.22.2.2
Notes Payable
9 Months Ended
Aug. 31, 2022
Debt Disclosure [Abstract]  
Notes Payable

Note 5 – Notes Payable

On August 20, 2016, the Company entered into a Credit Agreement (“Credit Agreement”) with Texas Capital Bank, National Association (“TCB”) for a term loan of $8.0 million in senior credit facilities. The proceeds of the term loan were used by the Company to fund repurchases of the Company’s common stock. Subject to the terms of the Credit Agreement, on August 20, 2016, TCB advanced the Company $100.00. On July 1, 2016, TCB advanced the remaining principal amount of $7,999,900 per a promissory note dated August 20, 2016 between the Company and TCB, at a rate of 3.75% per annum plus LIBOR, payable monthly with a maturity date of July 2021 which was extended to June 2022 pursuant to the Second Amendment to Credit Agreement discussed below. On August 26, 2016, the Company entered into a First Amendment to Credit Agreement with TCB. Pursuant to terms of the First Amendment to Credit Agreement, on August 26, 2016, TCB made an additional advance to the Company in the principal amount of $2,133,433 per an Amended and Restated Promissory Note dated August 26, 2016 between the Company and TCB. The additional proceeds of the term loan were used by the Company to fund the extinguishment of revenue sharing agreements. On June 11, 2018, the Company entered into a Second Amendment to Credit Agreement with TCB. Pursuant to the terms of the Second Amendment to Credit Agreement, TCB increased the current outstanding principal amount of the loan from TCB by $9,000,000 to finance a portion of the purchase price of the Cord:Use Purchase. In connection therewith, Cryo-Cell executed and delivered to TCB a Second Amended and Restated Promissory Note, in the principal amount of $15,500,000. As of the three and nine months ended August 31, 2022, the Company paid interest of $370 and $18,485, respectively, which is reflected in interest expense on the accompanying consolidated statements of income. As of the three and nine months ended August 31, 2021, the Company paid interest of $25,862 and $99,294, respectively, which is reflected in interest expense on the accompanying consolidated statements of income.

Collateral of the term and subordinated loans includes all money, securities and property of the Company.

The Company incurred debt issuance costs related to the term loan in the amount of $548,085 which is recorded as a direct reduction of the carrying amount of the note payable and amortized over the life of the loan. As of the three and nine months ended August 31, 2022, $592 and $10,368, respectively, of the debt issuance costs were amortized and are reflected in interest expense on the accompanying consolidated statements of income. As of the three and nine months ended August 31, 2021, $12,390 and $47,462, respectively, of the debt issuance costs were amortized and are reflected in interest expense on the accompanying consolidated statements of income.

As of July 1, 2022, the Company paid the term loan in full. The Company has no further obligations under the Credit Agreement.

On July 18, 2022, the Company entered into a Credit Agreement (“Agreement Susser”) with Susser Bank, a Texas state bank, as administrative agent (“Susser”) on behalf of itself and the other lenders (collectively, the “Lenders”) for (i) a revolving credit facility in an aggregate principal amount of up to $10,000,000 (the “RCF”); and (ii) a term loan facility in an original principal amount of $8,960,000 (the “Term Loan Susser” and together with the RCF collectively, the “Loans”). In connection with the RCF the Company entered into a Revolving Credit Note, in favor of Susser, in the stated principal amount of $10,000,000 (the “RCF Note”), and in connection with the Term Loan the Company entered into a Term Note, in favor of Susser, in the stated principal amount of $8,960,000 (the “Term Note” and together with RCF Note, collectively, the “Notes”).

The Loans bear interest at the Monthly SOFR plus 3.25% (subject to a floor of 4.5%). The RCF Note matures on July 18, 2025 and the Term Note matures on July 18, 2032.

On July 29, 2022, the Company entered into an Amendment to Credit Agreement (“Amendment”) with Susser on behalf of itself and the lenders. The Company is exposed to interest rate risk related to its variable rate debt obligation under the Term Note. In July 2022, the Company entered into an interest rate swap agreement with Susser to manage exposure arising from this risk. The swap agreement has a notional amount equal to the Term Note. The agreement pays the Company monthly SOFR plus 3.25% on the notional amount and the Company pays a fixed rate of interest equal to 6.09%. The effective date of the amended term loan was July 29, 2022 with a maturity date of July 29, 2032. As of August 31, 2022, the fair value of the derivative was recorded in deposits and other assets on the accompanying consolidated balance sheet in the amount of $62,835. Changes in the fair value of the derivative are recorded as a gain or loss on a derivative on the accompanying consolidated statements of income. For the three and nine months ended August 31, 2022, the Company recorded $62,835 and $62,835, respectively, as a gain on a derivative.

The proceeds of the Term Loan Susser were used by the Company to purchase a commercial office building and associated property in Durham, North Carolina, as described in Note 9. On September 2, 2022, subsequent to the balance sheet date, the Company used $7,672,728 of the RCF to distribute a Special Dividend to the Company’s stockholders as described in Note 9. The Company may also use the proceeds of the RCF, if needed, for general working capital needs and/or share repurchases.

The Company incurred debt issuance costs related to the loans in the amount of $196,501 which is recorded as a direct reduction of the carrying amount of the Term Loan Susser and amortized over the life of the loans.

As of August 31, 2022 and November 30, 2021, the note payable obligation was as follows:

 

 

 

August 31, 2022

 

 

November 30, 2021

 

Note payable - TCB

 

$

 

 

$

1,908,433

 

Note payable - Susser

 

 

8,960,000

 

 

 

 

Unamortized debt issuance costs - TCB

 

 

 

 

 

(10,368

)

Unamortized debt issuance costs - Susser

 

 

(196,501

)

 

 

 

Net note payable

 

$

8,763,499

 

 

$

1,898,065

 

Current portion of note payable

 

$

154,252

 

 

$

1,898,065

 

Long-term note payable, net of debt issuance costs

 

 

8,609,247

 

 

 

 

Total

 

$

8,763,499

 

 

$

1,898,065

 

 

Interest expense on the note payable for the three and nine months ended August 31, 2022 and 2021 was as follows:

 

 

 

For the three months ended

 

 

For the nine months ended

 

 

 

August 31, 2022

 

 

August 31, 2022

 

Interest expense on notes payable - TCB

 

$

370

 

 

$

18,485

 

Interest expense on notes payable - Susser

 

 

89,585

 

 

 

89,585

 

Debt issuance costs - TCB

 

 

592

 

 

 

10,368

 

Total interest expense

 

$

90,547

 

 

$

118,438

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the three months ended

 

 

For the nine months ended

 

 

 

August 31, 2021

 

 

August 31, 2021

 

Interest expense on notes payable - TCB

 

$

25,862

 

 

$

99,294

 

Debt issuance costs - TCB

 

 

12,390

 

 

 

47,462

 

Total interest expense

 

$

38,252

 

 

$

146,756